Mounjaro KwikPen change from April 2026 and the "golden dose"
Reviewed and fact-checked by Alessandro Grenci, Superintendent Pharmacist. Read our editorial policy to see how we create informative, accurate content.
Mounjaro (tirzepatide) is supplied in a multi-dose, disposable KwikPen that is designed to deliver four fixed weekly doses. Some people notice leftover liquid after the fourth dose and refer to it online as a "golden dose". A modified KwikPen is expected to appear in the UK from April 2026 to reduce leftover medicine and make it clearer when the final dose has been given. During the changeover, you may see both pen versions in circulation for a period of time.
Key takeaways
- Each Mounjaro KwikPen is intended to provide 4 fixed weekly doses, then the pen should be disposed of.
- Leftover liquid can remain after the fourth dose. This does not mean there is a safe, measured extra dose available.
- A modified pen is expected to reduce leftover medicine and make it clearer when the pen is ready to be discarded, while working the same way as the initial device.
- Do not try to extract extra doses or "microdose" from residual liquid. It is not calibrated for dosing and can increase the risk of dosing errors and contamination.
- If you are unsure which pen you have or how to use it, speak to a pharmacist, your prescriber, or your GP before your next injection.
What is changing with the Mounjaro KwikPen in 2026
The manufacturer has described a modified Mounjaro KwikPen intended to reduce leftover medicine and make it easier to track that the final dose has been administered, indicating the pen is ready to be discarded. The modified KwikPen works in the same way as the initial device.
The modified KwikPen is expected to become available in the UK from April 2026. Once existing stock of the initial device is depleted, supply is expected to transition to the modified device. During this period, both versions may be available in the market for some time across dose strengths.
What stays the same
Both the initial and modified Mounjaro KwikPens are disposable, multi-dose, single patient use pre filled pens. They contain the volume of solution necessary for priming before each injection and the delivery of 4 fixed 0.6 mL doses, with one dose administered weekly.
What may look different on the modified pen
The modified pen is reported to include visual and structural updates while maintaining the same use method.
Plunger position
The plunger sits further down in the cartridge when the pen is unused.
Extended plunger
A new internal component has been added behind the plunger, extending its length. This may be shown in the "Guide to Parts" section of the Instructions For Use supplied with the pen.
Clearer end of pen indication
After the fourth dose, the plunger is expected to be near the end of the pen, making it clearer that the pen is ready to be discarded.
Why there can be leftover liquid in the pen
Because the pen is designed for correct operation and priming, you may still see liquid in the cartridge after the fourth dose. This does not mean there is another measured dose available. The Instructions For Use describe the pen as providing four doses, and any remaining solution after use should be discarded with the pen.
Important: do not use the lines on the cartridge as dose indicators.
What is the "golden dose"
"Golden dose" is a non-medical term used online to describe leftover liquid that may remain after the fourth dose has been delivered.
It is not an approved dosing step. It is not part of the intended dosing schedule. It is not calibrated to deliver a prescribed amount.
Why you should not use the leftover liquid
Using leftover liquid is not recommended because it introduces avoidable risks.
1) It is not a validated dose
The KwikPen is designed to deliver fixed doses via its normal mechanism. Residual liquid is not presented as a calibrated, prescribed dose. Attempting to use it can lead to underdosing or overdosing.
2) It increases contamination risk
Trying to withdraw liquid by altering the pen, reusing parts, or using non-standard methods can compromise sterility. That increases the risk of local infection and other complications.
3) It increases side effect risk through dosing error
Tirzepatide can cause gastrointestinal side effects, and there are important warnings around dehydration and pancreatitis symptoms. Taking a non-prescribed amount can worsen tolerability and delay appropriate medical review.
Microdosing is not considered safe
Some online discussions mention "microdosing" by extracting smaller amounts from leftover liquid. This is not advised. The pen is not designed for dose splitting, and it can increase the risk of inaccurate dosing and contamination.
If you are struggling with side effects, do not change your dose yourself. Speak to your prescriber. Dose adjustments should be clinically supervised and follow the approved dosing schedule.
How Mounjaro is intended to be used, in brief
- Mounjaro is taken once weekly by subcutaneous injection.
- Each KwikPen is intended to provide 4 fixed doses, one dose per week, then the pen should be disposed of.
- Follow the Instructions For Use supplied with your pen carefully.
If you think your pen is faulty, do not try to force it or extract liquid. Seek advice from your pharmacist or prescriber.
FAQ
Is there a fifth "golden dose" in a Mounjaro pen?
You may see leftover liquid after the fourth dose, but the KwikPen is intended to provide four fixed doses. Any remaining solution should be discarded with the pen.
Why is there liquid left after the fourth dose?
The pen can contain extra solution needed for correct function and priming. It is not presented as an additional measured dose.
When will the modified Mounjaro pen be available in the UK?
The modified KwikPen is expected to become available in the UK from April 2026, with a transition period where both versions may be seen. Timing can vary by supply chain.
Does the modified pen change my prescribed dose?
No. The pen is still intended to deliver four fixed weekly doses. Always follow the Instructions For Use supplied with your pen.
Can I microdose by taking a smaller amount from leftover liquid?
No. Self-adjusting doses and extracting residual liquid is not recommended. Speak to your prescriber if you are struggling with side effects or feel your dose needs review.
What should I do if my pen seems faulty or tampered with?
Stop using it and contact your pharmacist or prescriber for advice. Do not try to extract doses or repair the pen yourself.
When to speak to a pharmacist or GP
Speak to a pharmacist, GP, or your prescriber if:
- You are unsure whether you have the initial or modified KwikPen, or you are not confident you have taken the fourth dose correctly.
- You have been considering using the leftover liquid or changing your dose schedule.
- You have troublesome side effects, especially ongoing vomiting or diarrhoea, or you cannot keep fluids down.
- You take other medicines and want to check for interactions, particularly medicines where timing and absorption matter.
- You think your pen may be faulty, damaged, or not genuine, or you have concerns about supply quality.
- References
References
Mounjaro KwikPen SmPC (electronic Medicines Compendium, UK)
https://www.medicines.org.uk/emc/product/15481/smpc
Mounjaro KwikPen Patient Information Leaflet (electronic Medicines Compendium, UK)
https://www.medicines.org.uk/emc/product/15481/pil
Mounjaro KwikPen Instructions for Use (user manual PDF on emc)
https://www.medicines.org.uk/emc/files/usermanual.15481.pdf
